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Abstract 
Portal hypertension is most commonly associated as a complication related to liver cirrhosis. 
Portal hypertension increases morbidity and mortality usually through gastrointestinal 
bleeding however other complications such as ascites formation and subsequent 
spontaneous bacterial peritonitis may occur. The degree of portal hypertension is already well 
established as a useful predictor of prognosis. Knowing this information will also help guide 
management. Currently treatment of portal hypertension is almost empirical without an easily 
accessible and safe method of monitoring portal pressure response and often it is unclear 
whether treatment targets have been attained. It is akin to treating arterial hypertension 
without a sphygmomanometer.  
 
Currently the gold standard and most frequently employed method of measuring portal 
hypertension is via the transjugular method at interventional radiology. This provides a 
measure of the free and wedged (or occluded) hepatic venous pressure from which the 
hepatic venous pressure gradient is derived. This gradient is currently the key value to 
determining risk of morbidity, mortality and guide management, in particular, when to provide 
active intervention or to help identify non responders to medical therapy. However this is not 
readily available (only in select expert centres) as this is a long and very technically 
demanding procedure to produce reliable and consistent clinical data. Therefore the need for 
an equally safe yet simpler procedure is needed.  
 
Endoscopic ultrasound guided portal pressure measurement is a novel technique whereby 
patients have their portal pressure gradient or hepatic venous pressure gradient measured 
with direct access into the portal vein and hepatic vein to calculate the hepatic venous 
pressure gradient. This procedure can be integrated into a session of diagnostic gastroscopy 
which is already a necessary component of the current management algorithm of portal 
hypertension. The gastroscopy can identify subjective endoscopic evidence of portal 
hypertension such as oesophageal varices and the endoscopic ultrasound guided portal 
pressure measurement can objectively quantify the degree of portal hypertension.  In this 
thesis the author presents the novel technique and results in animal as well as the first 
human pilot study which has shown great promise and has paved the way for a larger 
international multicentre trial to be commenced in the near future.
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Chapter 1 – Background and literature review 
1.1 Background 
Portal hypertension (PH) can be a complication related to liver cirrhosis1 or a vascular 
disorder2 such as Budd Chiari or extrahepatic portal venous obstruction. Majority of the non-
cirrhotic causes of PH are positioned in the pre or post hepatic zones. Given PH is more 
commonly related to liver cirrhosis, this thesis is focused specifically on liver cirrhosis (or 
sinusoidal) induced PH as opposed to PH related to primary vascular disorders.   
 
Liver cirrhosis 
Liver cirrhosis is a consequence of chronic liver injury secondary to a variety of aetiologies 
including but not limited to viral (e.g. hepatitis B or C), metabolic (e.g. haemochromatosis, 
Wilson’s disease, fatty liver disease), toxin mediated (e.g. alcoholic liver disease) or 
autoimmune processes (e.g. Autoimmune hepatitis, primary biliary cirrhosis, primary 
sclerosing cholangitis). Given that liver cirrhosis is the leading cause of PH in the western 
world,3 an overview of the concurrent mechanisms and changes within the liver parenchyma, 
regulatory mechanisms and impact on the vasculature are outlined below. 
 
1. Architecturally, chronic liver injury invariably leads to necroinflammatory reaction, 
diffuse nodular regeneration, dense fibrous tissue deposition and finally the collapse of 
liver architecture and ultimately distortion of liver parenchyma which also results in 
vascular distortion and altered flow resistance. Functionally this impairs blood flow 
though the liver parenchyma leading to progressive elevation portal flow resistance 
manifesting as PH as the progressive elevation in pressure is redistributed throughout 
the venous network.  
 
2. During progression to cirrhosis endogenous vasoconstricting factors are upregulated 
through increased activity of vasoconstrictive mediators such as endothelin, 
noradrenaline, angiotensin 2, vasopressin, leukotrienes and thromboxane A2. The 
heightened response to these vasoconstrictors by the vascular smooth muscle cells 
ultimately results in elevated hepatic vascular resistance therefore contributing to the 
degree or severity of PH.4  
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3. Vasodilating effects are also down regulated due to inhibition of nitric oxide release 
largely due to low endothelial nitric oxide synthetase activity5 hence further 
compounding this issue of PH. 
 
The prevalence of liver cirrhosis is estimated to be 0.27% in the United States.6 Cirrhotic 
patients are known to carry a higher risk for development of PH, most commonly manifesting 
as oesophageal varices. A cirrhotic patient has a risk of up to 8% per year for developing 
varices and 10% risk per year of these varices enlarging.7 Unfortunately, most cirrhotic 
patients will develop varices at some stage throughout the course of their disease therefore 
early identification and treatment is ideal, as severity of cirrhosis progress, the risk of 
developing varices increase. For example, a Child’s Pugh Class A patient may have up to 
40% chance of developing oesophageal varices compared to a more advanced 
decompensated Child’s Pugh Class C cirrhotic whom may have up to an 85% risk.7 Generally 
the risk of bleeding from varices is up to 15% per year. If left untreated, the rebleeding risk 
within 2 years is up to 60%.8 The mortality rate at 6 weeks post an index variceal bleed is up 
to 26%.9-11 
 
Portal hypertension 
The blood flow through the portal vein in healthy volunteers is estimated to be approximately 
13.5ml/min/kg12 as it receives blood flow from the small and large intestine as well as from 
intra-abdominal organs such as spleen and pancreas via the mesenteric veins (both superior 
and inferior) and the splenic vein. The portal vein also receives venous blood flow from the 
oesophagus and stomach via the left gastric vein. Obstruction to this flow cascade at the 
level of the portal vein or downstream sinusoids can result in PH and consequent 
engorgement or enlargement of other intra-abdominal veins which communicate with the 
systemic circulation such as the umbilical vein and epigastric venous plexus of the abdominal 
wall, superior haemorrhoidal veins and the middle/inferior haemorrhoidal veins and the short 
or left gastric with the azygos vein which in turn can result in complications at those particular 
anatomical sites.13, 14 The negative sequelae of PH are not only confined to variceal formation 
and consequent gastrointestinal bleeding, however, it also includes development of 
abdominal ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, 
hepatopulmonary or portopulmonary syndrome and ultimately death14. Therefore, being able 
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to quantify the degree of PH is of paramount importance in establishing a diagnosis, guiding 
treatment and monitoring of PH. 
 
PH is quantified by the portal pressure gradient (PPG), which derived from the difference 
between the portal venous (PV) pressure and the pressure within the hepatic vein (or inferior 
vena cava)1. It reflects the hepatic perfusion pressure. In patients with cirrhosis, portal 
pressure increases due to increased intrahepatic vascular resistance and increased portal 
blood flow overall. 
 
Portal pressure gradient measurement (PPGM) may be performed directly through PV 
puncture, and hepatic vein (HV) pressure may also be measured directly, allowing for 
calculation of PPG. However, portal pressure is usually determined indirectly by subtracting 
the free hepatic venous pressure (FHVP) from the wedged hepatic venous pressure (WHVP). 
In cirrhotic patients, the WHVP equals portal (sinusoidal) pressure, as the catheter in the 
occluded position forms a continuous column of fluid between the catheter itself, the blood in 
the HV, the sinusoids and the PV. This gradient is termed the hepatic venous pressure 
gradient (HVPG) which accurately reflects the degree of PH in all forms of sinusoidal and 
post-sinusoidal causes of portal hypertension.15, 16  
 
Overall, the severity of PH is an independent factor for survival in patients with liver cirrhosis 
15 and can be associated with common sequelae such as variceal bleeding and formation of 
ascites and less common syndromes such as portopulmonary, hepatopulmonary or 
hepatorenal syndrome. In certain circumstances, when the primary cause of liver cirrhosis is 
treated, the degree of PH can improve significantly. For example, anti-viral therapy for 
chronic hepatitis B infection,17 reduced mean portal pressure from 14.4mmHg to 12.4mmHg 
and 77% of patients experienced a significant reduction to below the 12mmHg, which is a 
major treatment target in order to significantly reduce the risk of gastrointestinal bleeding or 
the subsequent associated mortality. 
 
The definition of PH is a HVPG > 5mmHg. HVPG of 6mmHg or more correlates well with liver 
cirrhosis18 and cirrhotic patients with HVPG of ≤10mmHg are very likely to remain in a 
compensated state at a median follow up of 4 years.19 A HVPG of > 10mmHg represents 
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clinically significant portal hypertension (CSPH) and it is usually a pre requisite to the 
development of ascites and variceal bleeding and re-bleeding as well as predicting 
development of jaundice, encephalopathy20 and hepatocellular carcinoma (HCC).21, 22 The 
risk of developing HCC in patients with HVPG of > 10mmHg vs < 10mmHg is 6 times 
greater.21 The presence of PH also predicts risk of decompensation in post liver transplant 
patients.23 HVPG is also an important predictor for surgical mortality post HCC resection in 
cirrhotic patients24-26. There was a significant difference in post-operative 90 day mortality 
between patients with HVPG of 12mmHg vs 8mmHg. Thus the diagnosis and quantification 
of PH has relevant diagnostic, prognostic and therapeutic implications.27-29  
 
Monitoring HVPG has been increasingly used to assess target reductions of portal pressure 
during secondary, and less commonly, primary pharmacological prophylaxis of variceal 
bleeding. It is well established that the risk of variceal bleeding is dramatically lowered if 
HVPG is reduced by 20% from baseline or an absolute value of <12mmHg is achieved.30-33 
Not all patients are responders (between 36%33 to 64%34) hence it would be useful to identify 
the non-responders and discontinue pharmacotherapy (propranolol or carvedilol) as 
appropriate and consider alternatives. Development of ascites may also be preventable if the 
HVPG is lowered by ≥ 10%.35 Without ascites, spontaneous bacterial peritonitis, a 
complication of cirrhosis which carries up to a 75% 2 year mortality rate,36 is unlikely to 
develop.  
 
The procedure most often used to diagnose PH in clinical practice is the transjugular 
portosystemic pressure gradient.  This percutaneous method is invasive, requires ionizing 
radiation, intravenous contrast, provides only indirect measurements and is rarely available 
as the service is confined to expert centers due to technical requirements of the procedure to 
ensure reliable and consistent outcomes.  The procedure is performed by placing a 
radiopaque catheter (either an occlusion balloon or a wedge catheter) into the right jugular 
vein and advancing it into the HV tributaries under fluoroscopic guidance.  A FHVP and 
WHVP are obtained, providing an indirect measurement of the PV pressure, and the HVPG is 
estimated by subtracting the former from the latter.  This can be inaccurate in cases of pre-
hepatic PH, such as PV thrombosis, and duplex ultrasonography is often also required.  
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Other methods, such as the surgical and transhepatic approaches, can be used for obtaining 
direct measurements; however these are more invasive and are seldom employed.   
 
Given the importance of quantifying severity of PH, a less invasive, adjunctive modality and 
more direct method would be ideal. A simpler and widely accessible approach available 
outside of expert centres which can be combined with a routine test is needed given the 
prevalence of liver cirrhosis, PH and the likely need for subsequent repeated examinations or 
pressure measurements during the monitoring phase.  
 
Portal pressure measurement 
The first animal experiment to measure mesenteric vascular pressure was reported in 1896.37 
In humans, the first portal circulatory manometry was performed surgically and directly into 
the splenic vein in 193738 and subsequently the portal venous pressure (PVP) was measured 
by direct cannulation at surgery in 1950.39 Shortly after, the WHVP was measured40 via the 
cubital fossa guided by fluoroscopy. This produced accurate results even compared to this 
day whereby 12 healthy individuals displayed a mean WHVP of 4.8mmHg and 7 cirrhotic 
patients exhibited a mean pressure of 20mmHg (11.5-32mmHg). The technique was further 
refined by introduction of the balloon occlusion (as opposed to catheter wedge) in 197941 
which improved technical ease of the procedure and allowed wider sampling of the venous 
tributaries draining towards the IVC as a previous study demonstrated different wedge 
locations could produce different results.34 Although WHVP is a close estimate of the PVP 
(excluding pre-sinusoidal conditions such as schistosomiasis and early primary biliary 
cirrhosis42), this is affected by intra-abdominal pressure. Therefore, in order to neutralise this 
variable, subtracting the FHVP from WHVP will yield the HVPG which is unaffected by intra-
abdominal pressure variations, as it is a gradient and both FHVP and WHVP are equally 
affected. HVPG is currently the preferred43 method for measuring PH to determine diagnosis, 
prognosis and treatment targets to lower morbidity and mortality related to liver cirrhosis. 
Despite this, transcutaneous (often transjugular) approach as a well established technique 
and the current gold standard,43 the degree of unacceptable variability in results or tracings 
can be up to 30%44 hence rendering this technique only exclusively useful in high volume 
expert centers.  
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Other potential drawbacks to this approach include inadvertent damage to the structures 
surrounding the internal jugular vein, use of ionising radiation, the need for injection of 
intravenous contrast and failure to negotiate tortuous venous anatomy for HV cannulation.  
 
EUS guided direct PV manometry was first reported in animal models in 2004.45 22G Fine 
needle aspiration (FNA) needles were used in 21 pigs to study feasibility of this novel 
approach. There were technical failures in 38% of pigs and periduodenal bleeding which 
prevented the authors from pursuing human studies (information obtained via private 
communications). 4 years later, the Johns Hopkins group, with the same objective, utilised a 
5.5fr ERCP catheter for direct PV manometry after gaining access to the PV via EUS FNA 
and wire guidance. PV measurements were obtained continuously for an hour and 2 of 5 pigs 
were survived to demonstrate no complications.46 These two studies employed complex set-
ups using fluid filled manometers and neither measured PPG which is the key pressure 
differential between the portal vein (PV) and inferior vena cava (IVC) or hepatic vein (HV). 
The results were somewhat inconsistent with the direct portal pressure varying between 11 to 
41mmHg, non of which were cirrhotic models. Since then, although no further studies 
described EUS guided PPG, there have been many studies showing safety in EUS facilitated 
direct access into the PV for various indications including multiple animal studies support 
safety45-50 of this procedure with bleeding adverse events only occurring with larger needles 
(19 and 22G) or anticoagulated swine undergoing transduodenal FNA 45, 50 and human 
studies demonstrating uneventful EUS-FNA of the PV with a 25G needle in thrombocytopenic 
liver patients.51, 52 and 19G needle for PV sampling53, 54 for pancreatic cancer cells.  
 
In this thesis, the author presents the first animal and human study of EUS-guided PPG 
measurement with a novel simplified technique using a fine 25-gauge needle and compact 
digital manometer with simultaneous correlation to the current gold standard, transjugular 
free and wedged hepatic venous pressure (WHVP).   
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1.2 Objective 
The key objectives were to develop a simple endoscopic approach which complements the 
already necessary routine screening gastroscopy for oesophageal or gastric varices which 
can also measure direct PPGM with high levels of safety, consistency, accuracy and 
accessibility, to ensure this technique can be widely disseminated. Therefore, in this thesis, a 
novel yet simple method of endoscopic ultrasound (EUS) guided PPG was developed and 
examined for its feasibility, accuracy (by comparison with current gold standard of the 
transjugular method) and safety.  
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1.3 Thesis Structure 
The structure of this thesis is developed around the core two papers which have already 
been published in Gastrointestinal Endoscopy. I begin with a background and literature 
review (Chapter 1) which then lead into the design and methods (Chapter 2) section followed 
by two core papers (Chapters 3 and 4) where the author had introduced a new method for 
direct PPGM first developed in an animal model (Chapter 3), with and without PH, and 
subsequently progressing to a human pilot study (Chapter 4).  
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Chapter 2: Design and methods 
2.1 Animal study 
2.1.1 Animal model 
The initial approach was to establish feasibility in an animal model and with dextran induced 
PH rather than producing a cirrhotic model. This also allowed real time tracking of dynamic 
pressure increases and decrease as the PV compensate for the fluid overload. 3 yorkshire 
pigs (approximately 50kgs) were used for EUS-PPG. All swine were placed under general 
anaesthetic and euthanised immediately upon completion of the procedures. Necropsy and 
survival were not performed.  
 
2.1.2 EUS procedure  
A linear echoendoscope (GF-UC140P-AL5, Olympus,Tokyo,Japan), 25G FNA-needle (Cook 
Medical,Winston-Salem,NC),  manometer and non-compressible tubing (Cook Medical, 
Bloomington, IN) were used.  
 
Measurements were conducted in the right hepatic vein (RHV), PV, IVC and aorta. All venous 
measurements were performed via the transgastric transhepatic approach (Figure 2). When 
evaluating RHV pressure, FNA needle placement was targeted at 2cm distal to the ostia. 
When targeting the left main PV, only the intrahepatic portion near the PV bifurcation was 
accessed. IVC was accessed at the level of the RHV ostia and aorta was accessed just 
above the coeliac takeoff. Up to 1ml of heparinized saline was flushed through the FNA 
needle prior to each EUS reading. Following 30-60 seconds of stabilization, the pressure was 
recorded and generally ≥3 separate readings per vessel per FNA were performed. 
Transjugular and EUS pressure transducers were zeroed at an identical level (mid axillary 
line). 
 
2.1.3 Interventional radiology (IR) procedure. 
Manometric data was obtained from the RHV (both free and wedged), IVC and aorta. 
External jugular venous cut down facilitated venous access while aortic pressure (at the level 
just above coeliac takeoff) was obtained via the femoral artery. A 5Fr 11mm balloon 
occlusion catheter connected to a pressure transducer and recorder was used. Calibration 
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was performed at 6.8cm (5mmHg), 13.6cm (10mmHg) and 20.4cm (15mmHg) of water. This 
procedure was performed by a radiologist.  
 
2.2 Human pilot study 
2.2.1 Human pilot study 
EUS-PPG was performed at a single tertiary academic center by 2 experienced 
endosonographers (KC and JH).  All cases were performed under moderate sedation or 
general anaesthesia in the supine position. Patients must be between the age of 18-75 with a 
history of liver disease or suspected cirrhosis. Exclusion criteria included pregnancy, 
significant bleeding risk (International Normalized Ratio (INR) > 1.5, platelet count < 50), 
active gastrointestinal bleeding and post sinusoidal portal hypertension. Feasibility was 
measured based on technical success, which was defined as successful PPG manometry in 
each case.  Complications that were documented via post-procedural interview of all patients 
in person in recovery and by telephone within the subsequent 48 hours. Medical records 
including patient demographics, imaging studies, laboratory, EUS, and manometry results 
were captured prospectively then retrospectively reviewed and analyzed. Full written 
informed consent was obtained from all patients. The study was approved by the Institutional 
Review Board for Human Research at the University of California, Irvine. 
 
2.2.2 Endoscopic Procedure 
Prior to EUS PPG measurement, a forward viewing endoscope (Olympus, Tokyo, Japan) was 
used to evaluate and document the endoscopic evidence of PH such as varices or portal 
hypertensive gastropathy (PHG). The apparatus for PPGM included a linear echoendoscope 
(GF-UC140P-AL5, Olympus, Tokyo, Japan), a 25G FNA-needle (Cook Medical, Winston-
Salem, NC, USA), and a compact manometer with non-compressible tubing (Cook Medical, 
Bloomington, IN, USA). The manometer was zeroed at the mid axillary line then the EUS 
scope was inserted. Measurements were conducted in the PV and HV where possible. If the 
HV was inaccessible due to anatomical limitations, the inferior vena cava (IVC) was targeted. 
When the PV was targeted, manometry was performed via a transgastric transhepatic, and 
less often a transduodenal transhepatic approach and only the intrahepatic portion near the 
PV bifurcation was accessed. Typically the scope was positioned in the vicinity of the IVC, 
followed by visualization of the HV ostia (opening of the HV as it junctions into the IVC). The 
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needle tip was placed 2cm distal to the ostia where possible. One ml of heparinized saline 
was flushed through the primed FNA needle (no stylet) prior to each EUS reading. Following 
30-60 seconds of pressure stabilization, the reading was recorded. Three separate readings 
per vessel were performed and a mean pressure was calculated. The FNA needle was 
withdrawal from the PV to the level of the liver capsule, color doppler was used to make sure 
there was no flow in the needle track before complete withdrawal of the needle into the scope 
channel. Intraprocedural prophylactic antibiotics were given. 
 
2.2.3 Definitions 
The universal definition of portal hypertension (PH) of >5mmHg and clinically significant 
portal hypertension (CSPH) of >10mmHg were used 19. 
Patients with liver disease were classified as high or low evidence for cirrhosis. A patient was 
deemed high evidence for cirrhosis if pre procedural clinical evaluation (e.g. clinical history, 
physical examination), laboratory, endoscopic or imaging demonstrated evidence was 
suggestive or consistent with portal hypertension.  
 
2.2.4 Statistical analysis  
Descriptive statistics including median, mean, standard deviation, minimum and maximum 
were calculated for continuous variable.  For categorical variables, frequency counts within 
categories were obtained and reported. The Shapiro-Wilk test was utilized to examine the 
normality of the PPG distribution for four clinical outcomes. Due to violation of the normality 
assumption, for each clinical outcome the Wilcoxon Rank Sum test was then applied to 
compare the location shifts of PPG distributions between subgroups of patients. In order to 
maintain an experiment-wise significance level of 0.05, the Bonferroni-Holm method was 
applied to adjust for multiple comparisons.  
 
Considering the non-normality of PPG, an alternative method of analysis also was utilized. 
The natural logarithm transformation was applied to PPG values. For the four clinical 
outcomes, pairs of means among patient subgroups were compared using two-sample t-tests 
with the Bonferroni-Holm method of multiple comparisons.  
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A binary variable was created by dichotomizing PPG values into two categories: > 5mmHg 
vs. ≤5mmHg. Logistic regression models were applied to estimate the odds of the presence 
of a clinical symptom with the PPG indicator as a predictor. All statistical analyses were 
performed with SAS v9.4. 
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3.1 Abstract 
Background and Aims: Portal hypertension (PH) is a serious adverse event of liver 
cirrhosis. The hepatic venous pressure gradient (HVPG) accurately reflects the degree of PH 
and is the single best prognostic factor in liver disease. Currently, PPG measurement is 
performed at interventional radiology (IR) with a standard transjugular approach requiring 
radiation and IV contrast. The aim of this study was to develop a novel EUS-guided system 
using a 25G FNA needle and compact manometer to directly measure PPG and to evaluate 
its performance and clinical feasibility. 
 
Methods: Experiments were performed in 3 swine under general anesthesia by 3 
proceduralists (KC, JS and JH). Manometry was performed in venous (Baseline and PH) and 
arterial (aorta) systems.. The PH model was created by rapid Dextran-40 infusion 
peripherally. Under EUS guidance, a 25G FNA needle with attached manometer was used to 
puncture (transgastric-transhepatic approach) and measure pressures in the portal vein (PV), 
right hepatic vein (RHV), inferior vena cava (IVC), and aorta.  With the IR approach, RHV 
(free and wedged), IVC, and aorta pressure were measured with an occlusion balloon. 
Pressure correlation was divided into three groups; low pressure (baseline), medium 
pressure (non-cirrhotic portal hypertensive model) and high pressure (arterial). Correlation 
between the two methods of measurement was charted in scatter plots and the Pearson’s 
correlation co-efficient (R) was calculated. 
 
Results: EUS identification, access and manometry was successful in all targeted vessels. 
There was excellent correlation (R=0.985 to 0.99) between EUS and IR methods in all 
pressure ranges. No adverse event occurred.  
 
Conclusion: This novel technique of EUS-PPG measurement using a 25G needle and novel 
manometer was feasible and demonstrated excellent correlation with the standard 
transjugular method throughout low, medium and high pressure ranges.  
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3.2 Introduction 
Portal hypertension (PH) is a serious adverse event of liver cirrhosis.14 Patients with portal 
hypertension are at risk of developing gastro-esophageal varices and related bleeding, 
ascites, hepatorenal syndrome and hepatic encephalopathy.27 The hepatic venous pressure 
gradient (HVPG) accurately reflects the degree of PH in all forms of sinusoidal and post-
sinusoidal causes. Knowing the HVPG can guide medical therapy, assess degree of liver 
fibrosis56, predict risk of decompensation and developing hepatocellular carcinoma. 43, 46  
However, the transjugular procedure to obtain the HVPG is invasive and not readily available, 
therefore, most patients with suspected PH do not undergo this procedure.  
 
Older studies have been conducted studying the feasibility of EUS guided Portal vein 
pressure (PVP) measurements. These studies have employed 5.5Fr catheters.46 and 22-
gauge (G) FNA needles45 and have been based on direct PVP measurement. These studies 
employed complex set-ups using fluid filled manometers and no studies measured the portal 
pressure gradient (PPG), that is, the pressure differential between the portal vein (PV) and 
inferior vena cava (IVC) or hepatic vein (HV).   
 
Here we present the first study of EUS-guided PPG measurement with a novel simplified 
technique using a 25G needle and compact manometer (figure 1) with simultaneous 
correlation to the current gold standard, transjugular free and wedged hepatic venous 
pressure (WHVP).  Feasibility and accuracy of this novel technique and setup was evaluated 
in a porcine model with and without PH. 
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3.3 Methods 
Animal model 
Three Yorkshire swine weighing 43.5-48 kg were sedated with Telazol/Xylazine followed by 
intubation and maintained in supine position with Isoflurane. Continuous monitoring for heart 
rate, respiratory rate, end-tidal CO2 and oxygen saturation was carried out throughout the 
experiment until euthanasia with pentobarbital/phenytoin. Pressure measurements were 
carried out at baseline hemodynamics and then post induction of non-cirrhotic portal 
hypertension by rapid peripheral infusion of Dextran-40 (≤1.5 liters). This study protocol was 
approved by the hospital’s Institutional Animal Care and Use Committee.  
 
EUS Procedure 
A linear echoendoscope (GF-UC140P-AL5, Olympus,Tokyo,Japan), 25G FNA-needle (Cook 
Medical,Winston-Salem,NC),  manometer and non-compressible tubing (Cook Medical, 
Bloomington, IN) were used.  
Measurements were conducted in the right hepatic vein (RHV), PV, IVC and aorta. All venous 
measurements were performed via the transgastric transhepatic approach (Figure 2). When 
evaluating RHV pressure, FNA needle placement was targeted at 2cm distal to the ostia. 
When targeting the left main PV, only the intrahepatic portion near the PV bifurcation was 
accessed. IVC was accessed at the level of the RHV ostia and aorta was accessed just 
above the coeliac takeoff. Up to 1ml of heparinized saline was flushed through the FNA 
needle prior to each EUS reading. Following 30-60 seconds of stabilization, the pressure was 
recorded and generally ≥3 separate readings per vessel per FNA were performed. 
Transjugular and EUS pressure transducers were zeroed at an identical level (mid axillary 
line). The procedure was conducted by 3 experienced endosonographers (KC, JS and JH). 
 
Interventional Radiology (IR) Procedure 
Manometric data was obtained from the RHV (both free and wedged), IVC and aorta. 
External jugular venous cut down facilitated venous access while aortic pressure (at the level 
just above coeliac takeoff) was obtained via the femoral artery. A 5Fr 11mm balloon 
occlusion catheter connected to a pressure transducer and recorder was used. Calibration 
was performed at 6.8cm (5mmHg), 13.6cm (10mmHg) and 20.4cm (15mmHg) of water.  
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Correlation 
In the RHV, IVC and aorta, the transjugular balloon catheter tip and FNA-needle tip were 
targeted at the exact same location within the vessel as confirmed on fluoroscopic venogram 
and EUS (figure 3) and paired manometric datasets were recorded simultaneously. Needle 
placement was very specific to maximize consistency and to establish a standardized venous 
manometry protocol. Pressure correlation was divided into three groups; low pressure 
(baseline), medium pressure (non-cirrhotic portal hypertensive model) and high pressure 
(arterial).  
 
Statistical Analysis 
Descriptive statistics including median, mean, standard deviation, minimum and maximum 
were calculated for continuous variables.  Correlation between the two methods of 
measurement was charted in scatter plots and the Pearson’s correlation co-efficient (R) was 
calculated. 
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3.4 Results 
Feasibility 
EUS identification and access into all targeted vessels was achieved without any failures. All 
desired pressure readings were able to be obtained in each of the vessels in all pigs.  
 
Data and Correlation 
Using EUS there were a total of 17 independent manometry measurements made in the 
portal vein, 17 in the hepatic vein, 9 in the IVC and 4 in the aorta.  Using the IR approach 
there were 17 wedged hepatic vein measurements, 17 free hepatic vein measurements, 9 
IVC measurements and 4 aortic measurements (See Table 1). There was excellent 
correlation between the EUS and IR approach at all pressure ranges. Pearson’s correlation 
co-efficient was 0.999 (all vessels, Figure 4A), 0.985 (all veins, Figure 4B), 0.988 (PV and 
WHVP, Figure 4C) and 0.986 (FHVP, Figure 4D).   
 
Hemodynamic Monitoring  
Every swine was hemodynamically stable (blood pressure, heart rate, oxygen saturation and 
end tidal carbon dioxide) throughout all procedures despite multiple punctures into a variety 
of blood vessels. Furthermore, there was no evidence of bleeding seen at EUS or contrast 
extravasation on fluoroscopy; including during induced portal hypertension. Necropsy, 
however, was not performed. 
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3.5 Discussion 
HVPG is the single most important predictor of variceal bleeding risk.43, 57, 58 The current 
transjugular techniques to obtain HVPG are invasive and not readily performed. Our novel 
EUS-guided technique using a 25G needle and compact manometer demonstrated no 
technical failures related to vascular access or manometry, and demonstrated excellent 
correlation with the standard transjugular method that were maintained throughout low, 
medium and high pressure ranges indicating that this novel EUS method is highly accurate.  
An EUS guided approach is an attractive option for several reasons. EUS has the advantage 
of minimizing bleeding risk as real-time Doppler facilitates avoidance of intervening vessels 
and provides confirmation of hemostasis within the needle tract prior to needle withdrawal. 
This novel technique uses a small 25G needle via a transhepatic approach, allowing the 
surrounding liver parenchyma to tamponade the needle path. Unlike WHVP obtained via the 
transjugular approach, the accuracy of direct PV manometry is not influenced by liver tissue 
compliance. Lastly, EUS is widely available and with our novel method of attaching a pocket-
sized battery-operated manometer, HVPG can be readily obtained in a rapid, convenient 
manner.  We propose calling this procedure EUS-guided portal pressure gradient (PPG) 
measurement, as it reflects the true gradient between direct portal vein and direct hepatic 
vein pressure measurements.  
 
Standardization of technique to ensure consistency is of paramount importance, as 
previously highlighted in the radiology literature.44 We measured the RHV no further than 2cm 
from the ostia. The transducer was leveled and fixed at the mid axillary line in the supine 
position. It was important to perform both PV and HV manometry as this would neutralize 
confounding factors such as respiratory motion or variation in the device zeroing level. 
Limitations of this study include that it was a non-survival study without necropsy which would 
preclude definitive diagnosis of potential adverse events related to EUS-PPG measurement 
such as subacute bleeding, infection or thrombosis.  However, there was no EUS evidence of 
bleeding or haematoma at the completion of the pressure measurements, despite multiple 
punctures into the same target areas. There have been several uncomplicated human and 
animal studies involving EUS-FNA of the PV for various indications. One study included 10 
patients who uneventfully underwent EUS-FNA of the PV with 19G needle for cancer 
diagnosis.53 Two human cases reported uneventful EUS-FNA of the PV with a 25G needle in 
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thrombocytopenic liver patients.51, 52 Multiple animal studies also support safety45-50 of this 
procedure with bleeding adverse events only occurring with larger needles (19 and 22G) or 
anticoagulated swine undergoing transduodenal FNA.45, 50 Lastly, our portal hypertension 
model did not incorporate coagulopathy related to synthetic dysfunction and the lack of a 
cirrhosis model therefore does not truly reflect the physiology of a cirrhotic liver and 
assessment of the impact of anatomical distortion on technical feasibility was not possible. 
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3.6 Conclusion 
This novel technique of EUS-PPG measurement using a 25G needle and compact 
manometer was shown to be feasible in a porcine model and demonstrated excellent 
correlation with the standard transjugular method in a wide range of vascular pressures. Early 
human clinical trials are currently underway to further evaluate this promising concept.  
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3.7 Figures and tables 
 
Figure 1. Compact pocket sized battery operated manometer. 
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Figure 2. Transgastric transhepatic EUS placement of 25G needle into the left main portal 
vein. 
 
 
 
 
Figure 3. Simultaneous placement of transjugular (IR) balloon (inflated) and 25G EUS needle 
in the right hepatic vein. A. EUS and B.  Fluoroscopy. 
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Figure 4. Correlation between transjugular and EUS 25G methods - (A) Correlation of 47 
paired manometric data points from all vessels (arterial and venous) (B) Correlation of 43 
paired manometric data points from all venous structures * denotes inferior vena cava, portal 
and hepatic vein. (C) Correlation of 17 paired manometric data points from WHVP and PV 
(D) Correlation of 17 paired manometric data points from FHVP/RHV.  
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Table 1. Manometric data from PV, FHVP/RHV, aorta by EUS and IR methods.  
 
  
PV 
 
WHVP 
 
FHVP 
 
IVC 
 
Aorta 
  EUS IR EUS IR EUS IR EUS IR 
Baseline 
Number 10 10 11 11 6  6 4 4 
Mean 
(mmHg) 
5.8 6.9 4 4 1.7 3.3 104.3 104.3 
(S.D) 
(mmHg) 
1.03 1.45 1.48 0.45 1.03 0.52 0.5 0.58 
Median 
(mmHg) 
5.5 7 4 4 1 3 104 104.5 
Range 
(mmHg) 
5-8 5-9 0-5 3-5 1-3 3-4 104-
105 
104-
105 
Portal 
hypertensive 
model 
Number 7 7 6 6 3 3   
Mean 
(mmHg) 
16.4 17.6 18.3 19 17 18.3   
(S.D) 
(mmHg) 
6.1 6.5 1.51 0.89 1.73 0.58   
Median 
(mmHg) 
14 16 18 19 16 18   
Range 
(mmHg) 
9-24 10-27 17-21 18-20 16-19 18-19   
Combined 
Baseline and 
Portal 
hypertensive 
model 
Number 17 17 17 17 9 9   
Mean 
(mmHg) 
10.2 11.3 9.3 9.1 7.5 9   
(S.D) 
(mmHg) 
6.6 6.8 7.2 7.4 7.76 7.52   
Median 
(mmHg) 
7 8 5 4 3 4   
Range 
(mmHg) 
5-24 5-27 0-20 3-21 1-19 3-19   
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4.1 Abstract 
Background & Aims:  
Portal hypertension (PH) is a serious complication of liver cirrhosis. The hepatic venous 
pressure gradient or portal pressure gradient (PPG) accurately reflects the degree of PH and 
is the single best prognostic indicator in liver disease. This is usually obtained by 
interventional radiology (IR) although it is not routinely performed.  
Recently, we developed a simple novel technique for Endoscopic Ultrasound (EUS)-guided 
PPGM. Our animal studies showed excellent correlation between EUS-PPGM and IR-PPGM. 
We now present the first human pilot study of EUS-PPGM in patients with liver disease.  
 
Methods:  
EUS-PPGM was performed by experienced endosonographers using a linear 
echoendoscope, a 25G FNA-needle and a novel compact manometer. The portal vein and 
hepatic vein (or inferior vena cava) were targeted via a transgastric/transduodenal approach. 
Clinical parameters of PH were evaluated in each patient. Feasibility was defined as 
successful PPGM in each patient.  Safety was based on complications captured via post-
procedural interview. 
 
Results:  
28 patients underwent EUS-PPGM with 100% technical success and no complications. PPG 
ranged from 1.5-19mmHg and had excellent correlation with clinical parameters of portal 
hypertension including the presence of varices (p=0.0002), PH gastropathy (p=0.007) and 
thrombocytopenia (p=0.036). PPG was increased in patients with high clinical evidence of 
cirrhosis (p=0.005). 
 
Conclusion:  
This novel technique of EUS-PPGM using a 25G needle and compact manometer is feasible 
and appears safe. Given the availability of EUS and the simplicity of the manometry setup, 
EUS-guided PPG may represent a promising breakthrough for procuring indispensable 
information in the management of patients with liver disease 
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4.2 Introduction 
Portal hypertension (PH) is a severe complication of liver cirrhosis. Clinical manifestations 
may include the formation of varices with associated gastrointestinal bleeding, ascites, 
encephalopathy or hepatorenal syndrome.27, 30 Therefore, the diagnosis and quantification of 
portal hypertension by measuring portal pressure holds tremendous therapeutic and 
prognostic implications27-29 
 
The portal pressure gradient (PPG) is the difference between the portal vein pressure and the 
pressure within the hepatic vein (or inferior vena cava). It reflects the hepatic perfusion 
pressure. In patients with cirrhosis, portal pressure increases because of increased 
intrahepatic vascular resistance and increased portal blood flow27. 
 
PPG is derived from subtracting the hepatic venous (HV) pressure from the portal venous 
(PV) pressure. These pressures ideally should be obtained through direct venous puncture. 
However, currently, the PV pressure is not routinely measured and is indirectly estimated 
based on the wedged hepatic venous pressure (WHVP) and only the hepatic venous 
pressure is a true direct measure. In the cirrhotic liver, the WHVP is quite similar to the PV 
pressure. This gradient is termed the hepatic venous pressure gradient (HVPG) which 
accurately reflects the degree of PH in all forms of sinusoidal and post-sinusoidal causes of 
portal hypertension 15, 16, 30.  
 
The definition of portal hypertension is a HVPG > 5mmHg. A HVPG of > 10mmHg represents 
clinically significant portal hypertension (CSPH) and it is usually a pre-requisite to the 
development of ascites and variceal bleeding. Monitoring HVPG may be useful in guiding 
pharmacological prophylaxis of variceal bleeding. The risk of variceal bleeding is dramatically 
lowered if HVPG is reduced by 20% from baseline or an absolute value of <12mmHg is 
achieved 30-33. Furthermore, the severity of portal hypertension is an independent factor for 
survival in patients with liver cirrhosis 15.  
 
The most common approach to quantifying portal hypertension in clinical practice is the 
transjugular route.  This method is invasive, involves radiation exposure, requires the use of 
intravenous contrast, and provides only indirect measurements of the PV pressure.  The 
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technique involves placement of a radiopaque catheter into the right HV via the jugular vein 
under fluoroscopic guidance.  A free HV pressure and a WHVP are obtained, and HVPG is 
calculated 15.  Other methods, such as surgical and transhepatic percutaneous approaches, 
can be used for obtaining direct measurements; however these are more invasive and are 
not performed in clinical practice.   
 
We have recently presented Endoscopic Ultrasound (EUS) guided portal pressure gradient 
measurement using a 25 gauge needle and a novel compact manometer in an animal model 
59 demonstrating  excellent accuracy and strong correlation with pressure values obtained by 
the gold standard transjugular wedged and free hepatic venous pressure measurements by 
Interventional Radiology. Here we present the first pilot study in humans demonstrating safe 
and accurate direct portal pressure gradient measurements without the need for ionizing 
radiation, transhepatic catheter placement or surgery.  
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4.3 Methods 
EUS-PPG was performed at a single tertiary academic center by 2 experienced 
endosonographers (KC and JH).  All cases were performed under moderate sedation or 
general anesthesia in the supine position. Patients between the age of 18-75 with a history of 
liver disease or suspected cirrhosis were considered for PPG measurement. Exclusion 
criteria included pregnancy, significant bleeding risk (International Normalized Ratio (INR) > 
1.5, platelet count < 50), active gastrointestinal bleeding and post sinusoidal portal 
hypertension. Feasibility was measured based on technical success, defined as a successful 
PPG measurement in each patient.  Safety was assessed based on complications that were 
captured via post-procedural interview of all patients in person in recovery and by telephone 
within the subsequent 48 hours. Medical records including patient demographics, imaging 
studies, laboratory, EUS, and manometry results were retrospectively reviewed and 
analyzed. Full written informed consent was obtained from all patients. The study was 
approved by the Institutional Review Board for Human Research at the University of 
California, Irvine. 
 
Endoscopic Procedure 
Prior to EUS guided pressure measurement, a forward viewing endoscope (Olympus, Tokyo, 
Japan) was used to evaluate and document the endoscopic evidence of portal hypertension 
such as varices or portal hypertensive gastropathy (PHG). The apparatus for PPG 
measurement included a linear echoendoscope (GF-UC140P-AL5, Olympus, Tokyo, Japan), 
a 25G FNA-needle (Cook Medical, Winston-Salem, NC, USA), and a compact manometer 
(Figure 1) with non-compressible tubing (Cook Medical, Bloomington, IN, USA). 
Prior to echoendoscope insertion, the manometer was zeroed at the mid axillary line. 
Measurements were conducted in the portal vein (PV) (Figure 2) and hepatic vein (HV) 
(Figure 3) where possible. If the HV was inaccessible due to anatomical limitations, the 
inferior vena cava (IVC) was targeted. When the PV was targeted, manometry was 
performed via a transgastric, and less often a transduodenal, transhepatic approach and only 
the intrahepatic portion near the PV bifurcation was accessed. Typically the scope was 
positioned in the vicinity of the gastroesophageal junction to first identify the IVC, followed by 
visualization of the HV ostia (opening of the HV as it junctions into the IVC). The needle tip 
was placed 2cm distal to the ostia  where possible. Needle placement was meticulous to 
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ensure consistency. A small amount (1ml) of heparinized saline was flushed through the 
primed FNA needle (no stylet) prior to each EUS reading. Following 30-60 seconds of 
pressure stabilization, the reading was recorded. Three separate readings per vessel were 
performed and a mean pressure was calculated. Upon withdrawal of the needle, just prior to 
leaving the liver capsule, color doppler was used to make sure there was no flow in the 
needle track. The needle was withdrawn from the liver capsule when no doppler signal was 
present within the needle track. Intraprocedural prophylactic antibiotics were given. 
 
Definitions 
The universal definition of portal hypertension (PH) of >5mmHg and clinically significant 
portal hypertension (CSPH) of >10mmHg were used 19. 
Patients with liver disease were classified as high or low evidence for cirrhosis. A patient was 
deemed high evidence for cirrhosis if pre procedural clinical evaluation (e.g. clinical history, 
physical examination), laboratory, endoscopic or imaging demonstrated evidence was 
suggestive or consistent with portal hypertension.  
 
Statistical analysis  
Descriptive statistics including median, mean, standard deviation, minimum and maximum 
were calculated for continuous variable.  For categorical variables, frequency counts within 
categories were obtained and reported. The Shapiro-Wilk test was utilized to examine the 
normality of the PPG distribution for four clinical outcomes. Due to violation of the normality 
assumption, for each clinical outcome the Wilcoxon Rank Sum test was then applied to 
compare the location shifts of PPG distributions between subgroups of patients. In order to 
maintain an experiment-wise significance level of 0.05, the Bonferroni-Holm method was 
applied to adjust for multiple comparisons.  
 
Considering the non-normality of PPG, an alternative method of analysis also was utilized. 
The natural logarithm transformation was applied to PPG values. For the four clinical 
outcomes, pairs of means among patient subgroups were compared using two-sample t-tests 
with the Bonferroni-Holm method of multiple comparisons.  
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A binary variable was created by dichotomizing PPG values into two categories: > 5mmHg 
vs. ≤5mmHg. Logistic regression models were applied to estimate the odds of the presence 
of a clinical symptom with the PPG indicator as a predictor. All statistical analyses were 
performed with SAS v9.4. 
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4.4 Results 
A total of 28 patients underwent portal pressure manometry in this study and pressures were 
successfully achieved in all 28 patients. Baseline patient data is outlined in Table 1. PPG 
values ranged from 1.5-19mmHg with a mean of 8.2mmHg. 15/28 (57.1%) had evidence of 
PH based on PPG of which 10/15 (66.7%) had CSPH. Eleven of 28 subjects had endoscopic 
evidence of either esophageal or gastric varices with all 11 (100%) having PH and 10 
(90.9%) patients having CSPH based on EUS-PPG measurement.  
 
Feasibility 
EUS identification and access into all targeted vessels was achieved without any failures. 
However, in 9/28 (32.1%) access to the HV was unfavorable due to anatomical distortion 
from cirrhosis including caudate lobe hypertrophy. In these cases, accessing the IVC was felt 
to be a better alternative in obtaining the PPG. For portal vein access, a transgastric 
approach was used with the exception of 4 (14.3%) cases where a transduodenal approach 
was used.  
 
Complications 
There were no intra or post procedural complications such as bleeding, perforation or pain 
seen in any patient. There were no infectious complications in particular.  
 
Clinical Correlation 
There was excellent association between PPG and clinical parameters (Table 2). The 
relationship between PPG levels among patient subgroups for clinical outcomes is shown in 
Figure 4. PPG levels were increased in those with high clinical evidence of cirrhosis 
(Wilcoxon Rank Sum Test, nominal p=0.005), and in those with varices (nominal p=0.0002), 
PHG (nominal p=0.007) and thrombocytopenia (nominal p=0.036), compared to those without 
these conditions. Similarly, natural log-transformed values of PPG reflected increased mean 
values in those with cirrhosis (t-test, nominal p=0.0015), varices (nominal p<0.0001), PHG 
(nominal p=0.0012), and thrombocytopenia (p=0.0359). The geometric means of natural log-
transformed PPG were 8.5mmHg and 3.5mmHg with and without high evidence for cirrhosis, 
respectively, 13.8mmHg and 3.9mmHg with and without varices, respectively, and 
11.9mmHg and 4.8mmHg with and without PHG, respectively. 
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Logistic regression models indicated that when a patient has PPG ≥ 5mmHg, the odds of 
high evidence of cirrhosis was 18.7 (95% confidence interval, 2.97, 180.66) times higher than 
a patient with a normal (< 5mmHg) measurement. In addition, when a patient has PPG ≥ 
5mmHg, the odds of having thrombocytopenia was 6.1 (9%CI, 1.19, 38.38) times higher than 
a patient with PPG < 5 mmHg. Platelet count also had a moderate negative correlation with 
PPG (R = -0.473).  
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4.5 Discussion 
This study demonstrates that EUS guided portal pressure measurement using a 25G needle 
and a novel compact manometer is feasible and appears safe in humans. There were no 
technical failures with PPG manometry and there were no complications in any patient. 
The importance of knowing the portal pressure in the management of portal hypertension is 
well documented. This frequently alters management at every phase of medical treatment, 
namely, initiation, dose titration, cessation, escalation of therapy and prognostication 20, 43, 60. 
It may also play a pivotal role in diagnosis and staging of advanced fibrosis or cirrhosis 56, 60.  
Unfortunately, readily obtaining the portal pressure is hindered by many factors and 
establishing a gradient (rather than PVP only) is necessary as discussed previously to 
minimise factors which could adversely affect the accuracy of portal pressure manometry. 
EUS-PPG measurement using this novel approach may be an excellent modality to 
overcome many of these barriers. EUS is now widely available and the PPG manometry 
setup is simple and portable. This procedure requires no iodinated contrast or ionizing 
radiation and is well tolerated by patients, recovering in a similar manner to routine 
gastroscopy. Furthermore, direct portal pressure measurement is likely to be more accurate 
than the indirect WHVP, particularly in non-alcoholic cirrhosis or primary biliary cirrhosis 61-64. 
 
There were no complications in this study even in the context of most of these patients 
suspected of having cirrhosis and some were also thrombocytopenic and coagulopathic. 
EUS-PPG measurement is likely a safe procedure as it is based on the well-established 
technique of EUS guided fine needle aspiration, which carries an excellent safety record 65, 66. 
Furthermore, the use of a small gauge needle in concert with high-resolution real time 
Doppler imaging and liver parenchyma tamponade upon needle withdrawal likely all 
contribute to the relative safety of this novel technique.  
 
There was excellent correlation between PPG measurement and clinical evidence of portal 
hypertension and clinical suspicion of liver cirrhosis.   Patients with a high probability for 
cirrhosis, evidence of thrombocytopenia, portal hypertensive gastropathy or varices had 
significantly elevated PPG measurements compared to those without. All patients with 
varices had portal hypertension based on EUS PPG.  
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The limitations of this study include the retrospective study design, a single center study with 
a relatively small cohort of patients. Patients did not have simultaneous transjugular HVPG 
measurements. Patients with suspected cirrhosis did not have a percutaneous liver biopsy.  
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4.6 Conclusion 
This study showed that EUS-guided portal pressure measurement using a 25G needle and 
compact manometer is feasible and appears safe in humans. This technique represents a 
promising breakthrough for procuring indispensable information in the management of 
patients with liver disease. This work sets the stage for larger clinical trials to establish its role 
in a wider spectrum of liver disease and portal hypertension.  
53 
 
Acknowledgements 
Research reported in this publication was supported by the National Cancer Institute of the 
National Institutes of Health under Award Number P30CA062203. The content is solely the 
responsibility of the authors and does not necessarily represent the official views of the 
National Institutes of Health.  
54 
 
4.7 Figures and tables 
 
Figure 1. Compact manometer 
 
55 
 
 
Figure 2. A)Endoscopic Ultrasound Image of transgastric transhepatic needle puncture 
into the portal vein with a 25G FNA needle B) Diagram representing EUS guided 
transgastric portal vein puncture. 
 
 
 
Figure 3. A) Endoscopic Ultrasound Image of transgastric transhepatic needle 
puncture into the hepatic vein with a 25G FNA needle. B) Diagram representing EUS 
guided transgastric hepatic vein puncture. 
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Figure 4. PPG levels according to presence or absence of clinical condition. Error bars 
denote standard deviation.  p values of Wilcoxon rank sum test. 
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Table 1. Baseline Patient Characteristics  
 n % 
 Patient Demographics 
  
Total 28   
Male subjects 18 64% 
Age (y), mean (range) 63, (30-
80) 
 
Etiology/Indication 
  
Viral hepatitis 15/28 53.6% 
EtOH   6/28 21.4% 
Increased LFTs  5/28 17.9% 
NAFLD   2/28 7.1% 
Bleeding risk 
  
Coagulopathic (INR > 1.2)   4/26*  15.4% 
Thrombocytopenic (<150k)   16/28  57.1% 
Urea > 30  3/28  12.5% 
Cirrhosis†     
High clinical evidence for cirrhosis   19/28  67.9% 
   
Varices present 
Portal hypertensive gastropathy 
  11/28 
 9/28 
 39.3% 
 32.1% 
   
*2 patients had incomplete data on INR, †suspected based on clinical parameters 
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Table 2. EUS-PPG Measurement Clinical Subgroup analysis 
 Cirrhosis Varices Gastropathy Thrombocytopenia 
 High 
Clinical 
Evidence 
of 
Cirrhosis 
Low 
Clinical 
Evidence 
of 
Cirrhosis 
p-value* Present Absent p-value* Present Absent p-value* Present Absent p-value* 
N 19 9  11 17  9 19  16 12  
Mean PPG 10.33 3.81 
0.005 14.37 4.26 0.0002 12.76 6.09 0.007      10.30      5.48 0.036 
Median 
PPG 
10.70 3.60  14.70 4.00  12.30 4.00  9.50 4.00  
Standard 
Deviation 
5.73 1.87 
 
3.75 1.85 
 
4.52 4.96 
 
6.13 3.76 
 
Minimum 1.70 1.50  6.50 1.50  6.00 1.50  1.70 1.50  
Maximum 19.00 8.00  19.00 8.00  18.00 19.00  19.00 14.30  
*P –value of Wilcoxon Rank Sum test  
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Chapter 5 - Discussion 
5.1. Implications of this study 
Knowing the HVPG has significant impact on clinical management of patients and future 
research related to liver cirrhosis or PH hypertension, however, it is not commonly done 
due to difficulties with access to this information. Most importantly, HVPG can predict risk 
of decompensation, in particular, variceal bleeding and/or re-bleeding. It is well known that 
variceal bleeding risk related to portal hypertension is much lower below 12mmHg and 
essentially zero when HVPG is < 10mmHg as varices are absent.67  This can also 
potentially guide management both in the acute setting whereby a higher HVPG predicts 
increased risk of rebleeding 68 therefore early TIPS may be considered as a more 
aggressive intervention over conventional endoscopic variceal band ligation. In the elective 
setting, it may impact on decision to band varices seen at screening endoscopy. It is also 
helpful in determining response to pharmacotherapy for PH. This will facilitate 
determination of the optimal medication dose to achieve the key pressure reduction targets 
hence optimising the clinical outcome particularly with regards to bleeding risk. In those 
who fail to achieve any meaningful response, the medication can be confidently 
discontinued. The effective end points could include HVPG reduction; by ≥ 20%, into the < 
12mmHg range or even 10% reduction whilst the HVPG is less than 12mmHg. Other 
potential indications could include assessment of peri-operative mortality prior to liver 
resection and predicting risk of developing HCC or facilitate studies on anti-fibrotic drugs69 
by providing a clear and accessible outcomes parameter.  
 
With EUS being widely accessible, EUS-PPG can be performed at the same session as 
the routine screening gastroscopy for endoscopic evidence of PH in patients with known 
risk factors. Unlike the transjugular approach, EUS-PPG requires no iodinated contrast or 
ionizing radiation and is well tolerated by patients (no pain), recovering in a similar manner 
to routine gastroscopy. Furthermore, direct portal pressure measurement is likely to be 
more accurate than the indirect WHVP, particularly in early primary biliary cirrhosis. This 
simple yet innovative method has been shown in Chapter 4 which correlated extremely 
well (R=0.986) with the current gold standard of transjugular method for procuring HVPG 
in the animal model through a wide range of pressures from low pressure 
(baseline/normal), medium pressure (non-cirrhotic portal hypertensive model) and high 
pressure (arterial). Subsequent human pilot study demonstrated feasibility and tight 
correlation with presence of portal hypertension in patients with clinical, endoscopic and/or 
biochemical evidence suggestive of liver cirrhosis. There were no complications in this 
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study despite majority of patients were suspected of having cirrhosis and some were also 
thrombocytopenic and coagulopathic as this technique is based on a well-established 
technique of EUS guided FNA, which carries an excellent safety record. The use of a small 
25G gauge needle in conjunction with high-resolution real time doppler imaging and liver 
parenchyma tamponade prior to needle withdrawal likely all contribute to the safety of this 
novel technique. The most feared complications, including bleeding and infection, did not 
occur. Prophylactic antibiotics were given however it may be the case in the future where 
this is proven to be unnecessary as we had adopted a very conservative approach and are 
proceeding with extreme caution. This technique was 100% successful in acquiring a 
PPG. 
Lastly, clinical implications aside, this novel method of acquiring HVPG can also be useful 
tool in many aspects of PH related research.  
 
5.2. Limitations 
The animal study (chapter 4) was a non-survival model therefore no specific safety data 
was generated other than lack of immediate complications as seen on real time doppler 
study. Although a wide pressure range was measured and correlated with a very high 
Pearson’s correlation co-efficient, the portal hypertensive model was non cirrhotic.  
The human study (chapter 5) was a single center pilot study consistent of only a small 
cohort of patients (28). Although the results are favourable, a larger multicentre study is 
needed to confirm safety and accuracy of this novel method for measuring HVPG. Further 
correlation with transjugular method can be considered if achievable. 
 
5.3. Future direction 
An multicentre study with transjugular HVPG correlation is in the planning phase to assess 
the safety and accuracy of EUS-PPG. If this technique is accepted as a main stream 
diagnostic tool, it will facilitate further research on the natural history, treatment and 
prognosis of portal hypertension. In the clinical setting, this technique could be used to 
help define which patients require endoscopic intervention and/or modification of 
medications to treat portal hypertension. The training requires in-depth knowledge of liver 
anatomy in order to identify the key vascular targets for manometry. No additional support 
personnel are required in an existing unit capable of EUS-FNA.  
 
5.4. Conclusion 
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EUS-PPG is a promising technique which improve the easy of access to the HVPG which 
is likely to induce a paradigm shift in the management algorithm for PH in a diagnostic, 
therapeutic and prognostic fashion, whether it is in an elective or emergency situation.  
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